Pharming Group (NASDAQ:PHAR - Get Free Report)'s share price gapped down prior to trading on Thursday . The stock had previously closed at $10.96, but opened at $10.69. Pharming Group shares last traded at $10.69, with a volume of 441 shares traded.
Analyst Upgrades and Downgrades
Separately, HC Wainwright reiterated a "buy" rating and issued a $37.00 price target on shares of Pharming Group in a research note on Thursday, March 14th.
Check Out Our Latest Stock Analysis on Pharming Group
Pharming Group Trading Up 0.5 %
The company has a market cap of $739.52 million, a P/E ratio of -78.71 and a beta of 0.16. The stock's 50 day moving average is $11.44 and its 200-day moving average is $11.71. The company has a current ratio of 4.16, a quick ratio of 3.41 and a debt-to-equity ratio of 0.62.
Pharming Group (NASDAQ:PHAR - Get Free Report) last posted its earnings results on Thursday, March 14th. The company reported ($0.03) earnings per share (EPS) for the quarter, missing the consensus estimate of $0.05 by ($0.08). The company had revenue of $81.20 million for the quarter, compared to the consensus estimate of $71.83 million. Pharming Group had a negative net margin of 4.13% and a negative return on equity of 4.53%. Research analysts anticipate that Pharming Group will post -0.02 earnings per share for the current fiscal year.
Hedge Funds Weigh In On Pharming Group
A hedge fund recently bought a new stake in Pharming Group stock. Orion Portfolio Solutions LLC acquired a new position in Pharming Group (NASDAQ:PHAR - Free Report) during the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor acquired 11,715 shares of the company's stock, valued at approximately $134,000. Institutional investors own 0.03% of the company's stock.
Pharming Group Company Profile
(
Get Free Report)
Pharming Group N.V., a biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally. The company's commercialized product is RUCONEST, a plasma-free rhC1INH protein replacement therapy for the treatment acute hereditary angioedema (HAE) attacks.
Further Reading
Before you consider Pharming Group, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Pharming Group wasn't on the list.
While Pharming Group currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering when you'll finally be able to invest in SpaceX, StarLink, or The Boring Company? Click the link below to learn when Elon Musk will let these companies finally IPO.
Get This Free Report
